Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by stockpatrolon Feb 08, 2023 5:12pm

461 Views

Post# 35275612

$AGN.c is taking steps forward with their clinical trials. U

$AGN.c is taking steps forward with their clinical trials. Using data from phase 1 DMT trials for stroke treatment, to launch phase 2 study for Q3 2023. In the same quarter, a phase 2b study of Ifenprodil for chronic cough with 180 patients will begin. Ifenprodil has received positive feedback from the FDA and ODD for IPF treatment, with the potential for another ODD for chronic cough following this study.

https://www.reddit.com/r/PharmaStock/comments/10vixiu/algernon_pharmaceuticals_agnc_agnpf/

<< Previous

Bullboard Posts

Next >>

3 Mid-Sized Stocks to Consider This Season